Download PDFPDF

Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Reply to Fowler: Clinical relevance of AMP challenge in asthma

    Dear Editor

    We thank Dr Fowler for allowing us to expand further on the subject matter of AMP provocation clinical relevance. Could AMP be the preferred challenge stimulus for monitoring treatment requirements in asthma and to establish the appropriate dose of inhaled GCS needed to control airway inflammation? Although the available evidence clearly indicates that AMP challenge has a selective ability to probe cha...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    AMP challenge in asthma

    Dear Editor

    Dr Polosa and colleagues provided an informative review of the mechanisms and clinical application of bronchial challenge with adenosine monophosphate (AMP) in asthma and COPD.[1] I would however contest their proposal that AMP may be the preferred challenge stimulus for monitoring treatment efficacy, as well as disease progression and severity when compared with direct agents such as methacholine, and a...

    Show More
    Conflict of Interest:
    None declared.